<DOC>
	<DOCNO>NCT02754726</DOCNO>
	<brief_summary>The purpose study find study drug nivolumab , albumin- bound paclitaxel , paricalcitol , cisplatin , gemcitabine give together safe effective combine treat advanced pancreatic cancer .</brief_summary>
	<brief_title>Combination Therapy Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Age ≥18 year age . 2 . Histologically cytologically confirm metastatic pancreatic ductal adenocarcinoma . 3 . Capable provide informed consent comply Trial procedure . 4 . Karnofsky Performance Status ( KPS ) ≥ 70 % . 5 . Life expectancy ≥ 12 week . 6 . Measurable tumor lesion accord RECIST 1.1 criterion . 7 . Women must able become pregnant ( e.g . postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . Both male female patient reproductive potential must agree use reliable method birth control study . 1 . Patients must receive previous radiotherapy , surgery , chemotherapy investigational therapy treatment metastatic disease . Prior treatment adjuvant set gemcitabine and/or 5FU gemcitabine administer radiation sensitizer allow , provide least 6 month elapse since completion last dose linger toxicity present . 2 . Palliative surgery and/or radiation treatment le 4 week prior initiation study treatment . 3 . Exposure investigational agent within 4 week prior initiation study treatment . 4 . Evidence central nervous system ( CNS ) metastasis ( negative imaging study , clinically indicate , within 4 week Screening Visit ) . 5 . History malignancy ( except cure basal cell carcinoma , superficial bladder cancer carcinoma situ cervix ) unless document free cancer ≥5 year . 6 . Laboratory value : Screening serum creatinine &gt; upper limit normal ( ULN ) ; total bilirubin &gt; ( ULN ) ; alanine aminotransferase ( ALT ) AST ≥ 2.5 ULN ≥ 5.0×ULN liver metastasis present ; absolute neutrophil count &lt; 1,500/mm3 , platelet concentration &lt; 100,000/mm3 , hematocrit level &lt; 27 % female &lt; 30 % male , coagulation test ( prothrombin time [ PT ] , partial thromboplastin time [ PTT ] , International Normalized Ratio [ INR ] ) &gt; 1.5×ULN unless therapeutic dos warfarin . 7 . Current , serious , clinically significant cardiac arrhythmia determine investigator . 8 . History HIV infection active chronic hepatitis B C. 9 . Active , clinically significant serious infection require treatment antibiotic , antiviral antifungal . 10 . Major surgery within 4 week prior initiation study treatment . 11 . Any condition might interfere patient 's participation study evaluation study result . 12 . Any condition unstable could jeopardize patient 's participation study . 13 . Patient transplant organ . 14 . Patients history autoimmune disease . 15 . Prior PD1 PDL1 therapy . 16 . Patients take chemo immunosuppressive steroid ( equivalent &gt; 20 mg hydrocortisone per day ) . 17 . Patients &gt; Grade 1 preexist peripheral neuropathy ( per CTCAE ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>